For the readers interested in the stock health of Arbutus Biopharma Corporation (ABUS). It is currently valued at $4.68. When the transactions were called off in the previous session, Stock hit the highs of $4.95, after setting-off with the price of $4.943. Company’s stock value dipped to $4.30 during the trading on the day. When the trading was stopped its value was $4.41.
Recently in News on December 10, 2020, Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects. Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (–1.44 log10, N=7, p<0.7). You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Arbutus Biopharma Corporation had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.02 on 07/24/20, with the lowest value was $0.88 for the same time period, recorded on 04/03/20.
Arbutus Biopharma Corporation (ABUS) full year performance was 95.13%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arbutus Biopharma Corporation shares are logging -48.07% during the 52-week period from high price, and 432.26% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.88 and $9.02.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3290019 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Arbutus Biopharma Corporation (ABUS) recorded performance in the market was 58.63%, having the revenues showcasing 47.99% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 351.43M, as it employees total of 80 workers.
Analysts verdict on Arbutus Biopharma Corporation (ABUS)
During the last month, 0 analysts gave the Arbutus Biopharma Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.33, with a change in the price was noted +0.70. In a similar fashion, Arbutus Biopharma Corporation posted a movement of +17.47% for the period of last 100 days, recording 3,171,060 in trading volumes.
Arbutus Biopharma Corporation (ABUS): Technical Analysis
Raw Stochastic average of Arbutus Biopharma Corporation in the period of last 50 days is set at 63.56%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 56.52%. In the last 20 days, the company’s Stochastic %K was 55.71% and its Stochastic %D was recorded 61.04%.
Let’s take a glance in the erstwhile performances of Arbutus Biopharma Corporation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 58.63%. Additionally, trading for the stock in the period of the last six months notably improved by 125.00%, alongside a boost of 95.13% for the period of the last 12 months. The shares increased approximately by 29.33% in the 7-day charts and went up by 21.49% in the period of the last 30 days. Common stock shares were driven by 47.99% during last recorded quarter.